Literature DB >> 25553598

Long-term follow up of feline leukemia virus infection and characterization of viral RNA loads using molecular methods in tissues of cats with different infection outcomes.

A Katrin Helfer-Hungerbuehler1, Stefan Widmer2, Yvonne Kessler3, Barbara Riond4, Felicitas S Boretti5, Paula Grest6, Hans Lutz7, Regina Hofmann-Lehmann8.   

Abstract

It is a remarkable feature for a retrovirus that an infection with feline leukemia virus (FeLV) can result in various outcomes. Whereas some cats contain the infection and show a regressive course, others stay viremic and succumb to the infection within a few years. We hypothesized, that differences in the infection outcome might be causally linked to the viral RNA and provirus loads within the host and these loads therefore may give additional insight into the pathogenesis of the virus. Thus, the goals of the present study were to follow-up on experimentally infected cats and investigate tissues from cats with different infection outcomes using sensitive, specific TaqMan real-time PCR and reverse transcriptase (RT)-PCR. Nineteen experimentally FeLV-A/Glasgow-1-infected cats were categorized into having regressive, progressive or reactivated FeLV infection according to follow-up of FeLV p27 antigen detection in the blood. Remarkably, regressively infected cats showed detectable provirus and viral RNA loads in almost all of the 27 tested tissues, even many years after virus exposure. Moreover, some regressively infected cats reactivated the infection, and these cats had intermediate to high viral RNA and provirus tissue loads. The highest loads were found in viremic cats, independent of their health status. Tissues that represented sites of virus replication and shedding revealed the highest viral RNA and provirus loads, while the lowest loads were present in muscle and nerve tissues. A supplementary analysis of 20 experimentally infected cats with progressive infection revealed a median survival time of 3.1 years (range from 0.6 to 6.5 years); ∼70% (n=14) of these cats developed lymphoma, while leukemia and non-regenerative anemia were observed less frequently. Our results demonstrate that the different infection outcomes are associated with differences in viral RNA and provirus tissue loads. Remarkably, no complete clearance of FeLV viral RNA or provirus was detected in cats with regressive infection, even up to 12 years after exposure. In several cases FeLV reactivation could be observed. Thus, retroviruses integrated as provirus into the host's genome, could not be eliminated completely by the host and maintained their full potential for replication and reactivation.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  FeLV; Latent infection; Reactivation; Retrovirus; Tissue loads; qPCR

Mesh:

Substances:

Year:  2014        PMID: 25553598     DOI: 10.1016/j.virusres.2014.12.025

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  18 in total

1.  Immunosuppression in a Comparative Study of Feline Leukemia Virus Vaccines.

Authors:  Hervé Poulet; Jean-Christophe Thibault; Alonso Masias
Journal:  Clin Vaccine Immunol       Date:  2015-12

2.  Molecular Detection of Feline Leukemia Virus in Oral, Conjunctival, and Rectal Mucosae Provides Results Comparable to Detection in Blood.

Authors:  Raphael Mattoso Victor; Juliana Marques Bicalho; Manuela Bamberg Andrade; Bruna Lopes Bueno; Luiza Rodrigues Alves de Abreu; Adriane Pimenta da Costa Val Bicalho; Jenner Karlisson Pimenta Dos Reis
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

3.  Retroviral DNA--the silent winner: blood transfusion containing latent feline leukemia provirus causes infection and disease in naïve recipient cats.

Authors:  Stefanie Nesina; A Katrin Helfer-Hungerbuehler; Barbara Riond; Felicitas S Boretti; Barbara Willi; Marina L Meli; Paula Grest; Regina Hofmann-Lehmann
Journal:  Retrovirology       Date:  2015-12-21       Impact factor: 4.602

Review 4.  Update on Canine and Feline Blood Donor Screening for Blood-Borne Pathogens.

Authors:  K J Wardrop; A Birkenheuer; M C Blais; M B Callan; B Kohn; M R Lappin; J Sykes
Journal:  J Vet Intern Med       Date:  2016 Jan-Feb       Impact factor: 3.333

5.  Putative progressive and abortive feline leukemia virus infection outcomes in captive jaguarundis (Puma yagouaroundi).

Authors:  Claudia Filoni; A Katrin Helfer-Hungerbuehler; José Luiz Catão-Dias; Mara Cristina Marques; Luciana Neves Torres; Manfred Reinacher; Regina Hofmann-Lehmann
Journal:  Virol J       Date:  2017-11-17       Impact factor: 4.099

6.  Performance of 4 Point-of-Care Screening Tests for Feline Leukemia Virus and Feline Immunodeficiency Virus.

Authors:  J K Levy; P Cynda Crawford; S J Tucker
Journal:  J Vet Intern Med       Date:  2017-02-03       Impact factor: 3.333

7.  Evaluation of rapid diagnostic test kits for feline leukemia virus infection using samples from naturally infected cats.

Authors:  Jiayou Liu; Thomas O'Connor; Melissa Beall; Ramaswamy Chandrashekar; Michael Lappin
Journal:  JFMS Open Rep       Date:  2016-10-05

8.  Rapid and sensitive insulated isothermal PCR for point-of-need feline leukaemia virus detection.

Authors:  Rebecca P Wilkes; Eman Anis; Dawn Dunbar; Pei-Yu A Lee; Yun-Long Tsai; Fu-Chun Lee; Hsiao-Fen G Chang; Hwa-Tang T Wang; Elizabeth M Graham
Journal:  J Feline Med Surg       Date:  2017-06-07       Impact factor: 2.015

9.  The Diagnosis of Feline Leukaemia Virus (FeLV) Infection in Owned and Group-Housed Rescue Cats in Australia.

Authors:  Mark Westman; Jacqueline Norris; Richard Malik; Regina Hofmann-Lehmann; Andrea Harvey; Alicia McLuckie; Martine Perkins; Donna Schofield; Alan Marcus; Mike McDonald; Michael Ward; Evelyn Hall; Paul Sheehy; Margaret Hosie
Journal:  Viruses       Date:  2019-05-31       Impact factor: 5.048

10.  Genotyping of feline leukemia virus in Mexican housecats.

Authors:  Hugo Ramírez; Marcela Autran; M Martha García; M Ángel Carmona; Cecilia Rodríguez; H Alejandro Martínez
Journal:  Arch Virol       Date:  2016-01-08       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.